TWiV 1064: Clinical update with Dr. Daniel Griffin
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In his weekly clinical update, Dr. Griffin discusses progress toward measles elimination, risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune-suppressive drugs, symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals, late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial, higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19, recombinant C1 inhibitor in the prevention of severe COVID-19, and Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Progress toward measles elimination (CDC)
- Risk of severe COVID-19 despite vaccination in patients using immune-suppressive drugs (TID)
- Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to untreated individuals (CID)
- Late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial (JID)
- Higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19 (JAMA)
- Recombinant C1 inhibitor in the prevention of severe COVID-19 (FII)
- Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with SARS-CoV-2 disease course (BMC)
- Contribute to our MicrobeTV fundraiser at PWB 37:55
- Letters read on TWiV on TWiV 1062 38:16
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]